Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Size: px
Start display at page:

Download "Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis"

Transcription

1 Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; Henry A. van Swieten, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Objective: To define prognostic parameters for patients with synchronous non-small cell lung cancer (NSCLC). Design: Retrospective study of period from 1970 through Patients: Patients with a single (n 2,764) and synchronous NSCLC (n 85) who underwent pulmonary resection. Methods: All tumors were classified postsurgically, and the tumors of the patients with synchronous lung cancer were staged separately. The most advanced tumor was used for comparison. Actuarial survival time was estimated, and risk factors influencing survival were evaluated. Patients who died within 30 days of surgery were excluded. Measurement and results: Five-year survival for single NSCLC was 41% and for synchronous lung cancer it was 19%. The relative risk of death for patients with synchronous lung cancer was 1.75, compared to that for patients with single lung cancer. The most advanced tumor in synchronous cancer was a significant predictor of survival (p < 0.005). The survival of patients with synchronous lung cancer in which the most advanced tumors were stage I (n 40) and stage II (n 27) was not different from that of patients with stage II (n 834) and stage IIIA (n 405) single lung cancer, respectively. Conclusion: The poorer survival of patients with synchronous NSCLC is confirmed and quantified. The stage of the most advanced tumor was the best predictor of prognosis. The prognosis of patients with synchronous NSCLC resembles the prognosis of patients with a single lung cancer of a higher stage. Upstaging in synchronous lung cancer is recommended on the basis of these observations. (CHEST 2000; 118: ) Key words: lung neoplasm; multiple primary neoplasm; neoplasm staging; non-small cell lung carcinoma; prognosis; pulmonary surgical procedures; survival Abbreviations: CI confidence interval; NSCLC non-small cell lung carcinoma *From the Departments of Pulmonary Diseases (Drs. van Rens, Zanen, and van den Bosch), Pathology (Dr. Elbers), and Thoracic Surgery (Dr. van Swieten), Sint Antonius Hospital, Nieuwegein; and Department of Thoracic Surgery (Dr. Brutel de la Rivière), University Medical Center, Utrecht, the Netherlands. Manuscript received November 16, 1999; revision accepted May 11, Correspondence to: Marcel Th. M. van Rens, MD, Sint Antonius Hospital, Department of Pulmonary Diseases, PO Box 2500, 3430 EM Nieuwegein, The Netherlands; antolong@knmg.nl Pulmonary resection remains the most effective treatment for patients with non-small cell lung cancer (NSCLC) with limited disease. 1 In some patients, more than one tumor is present or a second one is detected later (multiple lung cancer). Generally, multiple lung cancer is subdivided into synchronous and metachronous lung cancer, 2 with synchronous cancer being defined as two or more tumors present or detected at the same time, and metachronous cancer being defined as tumors detected with an interval. However, diagnosis of multiple lung carcinoma with the same histology may be difficult because of the possibility of metastatic or recurrent disease. 2 There have been several studies of synchronous lung cancer, 3 8 and these studies should be distinguished from those analyzing primary lung cancer with intrapulmonary metastasis In general, the data of patients with synchronous lung cancer are not related to therapy and survival of patients with single lung carcinoma. Therefore, it remains difficult to probe changes in survival of patients with synchronous lung cancer. 952 Clinical Investigations

2 In this report, the results of surgical treatment of patients with synchronous lung cancer are compared with those for patients with single lung carcinoma. Possible prognostic parameters in synchronous lung cancer are defined. Materials and Methods From 1970 through 1997, a total of 3,372 previously untreated patients underwent surgery for NSCLC at the Sint Antonius Hospital, Nieuwegein, the Netherlands. Of these, 3,086 patients underwent pulmonary resection, 2,849 of whom underwent resection for stage I, stage II, and stage IIIA NSCLC. These patients were allocated to two groups. The first group consisted of 85 patients with synchronous lung carcinoma. In 27 of these 85 patients, the second tumor was found accidentally at operation or at pathologic examination. In all 85 patients, the tumors were diagnosed at the same time and were classified as synchronous lung cancer according the criteria of Martini and Melamed 2 (Table 1). The second group consisted of 2,764 patients with single NSCLC. Recently, 2,361 of these patients with a follow-up of at least 5 years were analyzed in a study validating refinements of the staging system. 14 The characteristics of the patients with a single lung cancer (n 2,764) and synchronous lung cancer (n 85) are presented in Table 2. Tumors were classified postsurgically, according to the 1997 staging system. 1 The tumors of patients with synchronous cancer were staged separately, and the highest staged/most advanced tumor was classified as the reference tumor, as reported by others. 4,5 Resected specimens were routinely examined pathologically and reviewed using the current criteria of the World Health Organization classification. 15 Differences in frequency-based patient data were tested by the 2 test and normally distributed data by Student s t test. Differences were considered significant when the p value was Two survival analyses were performed. One analysis used the data for both patients with single or synchronous lung cancer, to focus on differences between single and synchronous lung cancer. The other analysis used only the data for the patients with synchronous lung cancer. Survival was calculated by the Kaplan- Meier survival analysis method. 16 Survival was estimated from date of operation. Deaths within 30 days after operation were excluded. Differences in survival between the two groups were tested by the log-rank test. 17 Differences were considered significant when the p value was To facilitate interpretation, the hazard ratio (plus 95% confidence interval [CI]) was calculated where needed. Multivariate Cox s regression analysis 18 was used to analyze the data of the patients with synchronous lung cancer, to test the relation between survival and age, stage of tumor, histology, or tumor localization. The following variables Table 1 Criteria for Synchronous Lung Cancer* Tumors present or diagnosed at the same time A. Tumors physically distinct and separate B. Histology Different Same, but in different segment, lobe, and lung if: Origin from carcinoma in situ No carcinoma in lymphatics common to both No extrapulmonary metastases at time of diagnosis *Adapted from Martini and Melamed. 2 Table 2 Characteristics of Patients With Single and Synchronous NSCLC* Characteristics Single Lung Cancer were used as categorical variables with two classes: age ( 65 years vs 65 years); histology (identical vs different); and tumor localization (one lobe vs different lobes). The variable stage was used as a categorical variable with three classes (stages I, II, and IIIA). A forward-selection approach was used. Results Synchronous Lung Cancer Patients, No. 2, Sex Male 2,528 (91.5) 76 (89.4) Female 236 (8.5) 9 (10.6) Age, yr Median ,328 (48) 49 (58) Unilateral 42 (49) One lobe 16 More than one lobe 26 Bilateral 43 (51) Histology Squamous 1,821 (65.9) 49 (57.6) Adeno 689 (24.9) 30 (35.3) Adenosquamous 98 (3.6) 6 (7.1) Large cell 156 (5.6) 0 Resection Pneumonectomy 710 (25.7) 14 (16.5) Lobectomy 1,649 (59.7) 53 (62.4) Bilobectomy 222 (8.0) 7 (8.2) Limited resection 183 (6.6) 11 (12.9) Side Right 1,483 (53.7) 47 (55.3) Left 1,281 (46.3) 38 (44.7) ptnm stage IA 510 (18.4) 18 (21.2) IB 954 (34.5) 32 (37.6) IIA 99 (3.6) 3 (3.5) IIB 781 (28.3) 26 (30.6) IIIA 420 (15.2) 6 (7.1) *Data are presented as No. (%) unless otherwise indicated. ptnm pathologic TNM. Details from reference tumor are presented. Segmental or wedge resection. From Mountain. 1 One hundred twelve patients (4.1%) with single lung cancer (n 2,764) and 12 patients (14.1%) with synchronous lung cancer (n 85) died within 30 days after operation. Eleven patients who underwent resection for synchronous lung cancer died because of cardiorespiratory complications. Postoperative mortality was especially high (6 of 28) among patients with bilateral lesions who underwent resection in one session. However, the characteristics and the causes of postoperative death did not differ from those of the other patients with synchronous lung CHEST / 118 / 4/ OCTOBER,

3 Table 3 Characteristics of Evaluable Patients With Synchronous Lung Cancers (n 73)* Characteristics No. Reference Tumor, No. Second Tumor, No. Histology 15 Identical 50 Different 23 Stage I I 40 II I 22 II II 5 IIIA II 6 Resection Pneumonectomy 13 (Bi)Lobectomy Limited resection 7 29 Tumor in first resection 25 *Deaths within 30 days are excluded. Reference tumor vs second lesion. Figure 2. Top: Estimated 5-year survival of patients with synchronous lung cancer with reference tumor stage I (n 40; broken line), compared to survival of patients with stage II single NSCLC (n 834; solid line; no survival difference; p 0.48). censored cases. Bottom: Estimated 5-year survival of patients with synchronous lung cancer with reference tumor stage II (n 27; broken line), compared to survival of patients with stage IIIA single NSCLC (n 405; solid line; no survival difference; p 0.52). censored cases. cancer. Eight patients with single lung cancer were unavailable for follow-up, and therefore the data for 2,717 patients (2,644 single and 73 synchronous lesions cancer) were included for detailed survival analysis. The characteristics of the 73 patients with synchronous lung cancer included in the analysis are given in Table 3, but were not different from those of the total group of 85 patients who underwent surgery for synchronous lung cancer. As of January 1, 2000, 9 of the 73 patients with synchronous lung cancer were alive, with survival times of 2.1 to 6.4 years (median, 4.6 years) and were free of cancer. Thirty-five of the 64 patients who died, died of recurrence or metastasis of lung cancer, and 20 died of noncancer-related causes; in 9 patients, the cause of death was not recorded. Recurrence or metastases was diagnosed at a median time of 12 months (range, 2 to 143 months) after resection. Figure 1. Estimated survival after resection of patients with single (n 2,644; solid line) and synchronous (n 73; broken line) NSCLC (p ). censored cases. Single and Synchronous Lung Cancer The demographic characteristics of the two groups did not differ. The patients with synchronous lung cancer were older (median age difference, 1.1 year), however not significantly (p 0.35), and the stage distribution of the single and reference tumor was not different (p 0.36). Overall survival was significantly higher (p ) in patients with a single lung cancer. Five-year survival after surgery was 41% 954 Clinical Investigations

4 Table 4 Median Survival and 5-yr Survival Rates After Resection for Single and Synchronous Lung Cancer* Single Synchronous Stage n Median, yr 5-yr Survival, % n Median, yr 5-yr Survival, % I 1, IA IB II IIA IIB IIIA II 1, *Reference tumor used as stage marker for comparison. From Mountain. 1 for patients with single lung cancer and 19% for patients with synchronous lung cancer (Fig 1). Survival after surgery in single lung cancer was significantly different between stage I and stage II disease (p ), stage II and stage IIIA disease (p ), and between subsets IA and IB (p ), and IIA and IIB (p 0.04). Using the reference tumor as stage marker in patients with synchronous lung cancer, there was no significant difference between subsets IA and IB (p 0.42; hazard ratio, 0.73; 95% CI, 0.34 to 1.55) and between subsets IIA and IIB (p 0.80; hazard ratio, 1.17; 95% CI, 0.34 to 4.00). Because of this observation and the small numbers of synchronous lung cancer patients, comparative analyses of subsets of patients with single and synchronous lung cancer were not done. The survival of patients with stage I synchronous lung cancer (n 40) was not significantly different (p 0.48; hazard ratio, 0.88; 95% CI, 0.61 to 1.26) from that of patients with stage II single lung cancer (n 834; Fig 2, top), and neither was the survival of patients with stage II synchronous lung cancer (n 27) significantly different (p 0.52; hazard ratio, 0.88; 95% CI, 0.58 to 1.31) from patients with stage IIIA single lung cancer (n 405; Fig 2, bottom; Table 4). The relative risk of death was 1.75 higher in patients with synchronous lung cancer than in patients with single lung cancer, irrespective of the stage of the disease. When the stage of the disease was taken into account, the relative risk of death ranged from 1.73 to 1.93 (Table 5). Synchronous Lung Cancer With the reference tumor as stage marker, survival was found to be significantly different for the different disease stages (stages I, II, and IIIA; p 0.005). Survival differed significantly between stage I and stage II disease (p 0.05) or stage IIIA disease (p 0.004), but not between stage II and stage IIIA disease (p 0.15; hazard ratio, 0.50; 95% CI, 0.20 to 1.28; Fig 3; Table 6). After pooling, the patients with stage II and stage IIIA disease had a significantly lower survival (p 0.01) than the patients with stage I disease. Five-year survival was 13% vs 23%, respectively (Fig 4; Table 6). According to the new staging system, 1 synchronous lesions with the same histology are classified as stage IIIB and stage IV. In the present survival analysis, 50 patients had synchronous lesions with the same histology. Although the numbers are small, a significant difference (p 0.03) in survival was found between patients with tumors located within one lobe (n 7; stage IIIB) and tumors located in different lobes (n 43; stage IV). The same result was found when the data of all the patients with Table 5 Cox s Proportional Hazards Model of Factors Associated With Postoperative Survival After Resection in Patients With Single and Synchronous Lung Cancer Variables Hazard Ratio 95% CI SE Synchronous vs single Stage I* Stage II* Stage IIIA* Stage II* *Synchronous vs single; in synchronous lung cancer, reference tumor is used as stage marker. No significant difference. CHEST / 118 / 4/ OCTOBER,

5 Figure 3. Estimated 5-year survival after tumor resection of patients with synchronous lung cancer with reference tumor stage I (n 40; solid line), stage II (n 27; intermediate broken line), and stage IIIA (n 6; broken line). censored cases. Figure 4. Estimated 5-year survival after tumor resection of patients with synchronous lung cancer treated by pneumonectomy or lobectomy(ies) (n 41; broken line), compared to surgical procedures including limited resections (n 32; solid line). censored cases. synchronous cancer (n 73) were analyzed (p 0.03; hazard ratio, 0.44; 95% CI, 0.22 to 0.90). Five-year survival was 29% and 16% for single and multiple lobe disease, respectively. Further analysis (Cox s regression analysis) demonstrated that this difference was related to the stage of the reference tumor. Kaplan-Meier analysis demonstrated that tumor histology did not affect survival (p 0.79). When the cases were grouped by histologic subtype, there was no significant difference in survival. Furthermore, the median survival was poorer in patients treated by a surgical procedure, including limited resection (such as a wedge or segmental resection; n 32), than it was in patients treated by pneumonectomy or lobectomy(ies) (n 41); however, this difference was not statistically significant (p 0.16; hazard ratio, 1.44; 95% CI, 0.86 to 2.40). Cox s regression analysis showed that the stage of the reference tumor was the only significant predictor of survival in patients with synchronous lung cancer (p 0.005); age (p 0.06), histology (p 0.90) and localization of tumors (p 0.11) were not. Survival was poorer when the reference tumor was higher than stage I (Table 6). Discussion This study confirms and quantifies the poorer postsurgical survival of patients with synchronous NSCLC, compared with that of patients with single NSCLC. The risk of dying of patients with synchronous lung cancer was almost double that of patients with single lung cancer. The stage of the most advanced tumor was the best predictor of survival in patients with synchronous lung cancer. Our results as well as the results of others show that surgery is a treatment option for patients with synchronous lung cancer. 3 8 Survival after resection in the patients with synchronous lung cancer was comparable with that reported in the literature. 3,6,8,19 For patients with stage IA single NSCLC, survival is poorer after limited resection. 20 However, in the present study, this observation was not confirmed clearly, possibly because several resections were performed. Never- Table 6 Cox s Proportional Hazards Model of Factors Associated With Postoperative Survival After Resection in Patients With Synchronous Lung Cancer Variables Hazard Ratio 95% CI SE Stage II reference tumor* Stage II reference tumor* Stage IIIA reference tumor* *Related to stage I reference tumor. 956 Clinical Investigations

6 theless, the use of limited resections for synchronous lesions is not supported and should be considered as a viable compromise surgical treatment. 20 In the literature, two separate definitions are used to define and stage synchronous malignant lesions in the lung. The time-dependent diagnosis (ie, synchronous vs metachronous) is rather definite. Malignant lesions have to grow before they can be detected. If CT and other scanning techniques had been available at time of diagnosis of all the patients, it is possible that more patients would have been diagnosed with synchronous cancer. However, we aimed to include only patients whose disease met the strict definitions used by Martini and Melamed. 2 These authors excluded synchronous tumors affecting common lymphatics if these had the same histology, because of possible metastatic disease. In contrast to former definitions, the new staging system limits the staging of multiple synchronous tumors to lesions with the same histology and possible metastatic disease. 1 Synchronous satellite pulmonary nodules situated in the same lobe are considered to be locally advanced disease and are staged as T4 (stage IIIB). Tumors located in different lobes are staged as metastatic disease (stage IV). 1 The definitions used by Martini and Melamed 2 and in the 1997 staging system 1 are debatable. Grossly, both definitions fail to implement the multiple field cancerization theory 21 and to deal with the possibility of metastatic disease. This is really a problem when the diagnosis is made on the basis of histology according to World Health Organization criteria 10 and the histology of both tumors is identical. In the future, new molecular techniques will make it possible to distinguish metastatic lesions from separate primary tumors. 22,23 Cancer staging is designed to determine therapy and prognosis. 1 In the new staging system, primary lung cancer with secondary pulmonary nodules is staged by upstaging, but there is no proposal for the staging of synchronous lung cancers. In order to analyze the meaning of staging and upstaging in synchronous disease, we first staged all tumors separately. The most advanced tumor was defined as the reference tumor. Because the stage of the reference tumor proved to be the main predictor of survival, we then compared patients with single and synchronous lung cancer according to the stage of the (reference) tumor. The survival of patients with synchronous lung cancer with stage I reference tumor appeared to be comparable to that of patients with stage II single lung cancer, and the survival of patients with synchronous lung cancer with reference tumor stage II appeared comparable to that of patients with stage IIIA single NSCLC. Although our study included relatively a small number of patients, our findings may help to stage synchronous multiple NSCLC and to determine prognosis. We propose that the reference tumor should be upstaged by one stage. Thus, patients with synchronous lung cancer with reference tumor of stage I and stage II are eligible for surgery and have a survival comparable to that of patients with primary stage II and stage IIIA NSCLC, in whom surgery is performed. In conclusion, the prognosis of patients with synchronous NSCLC is worse than that of patients with single NSCLC. After resection, the risk of dying is almost double that of patients with single NSCLC. The stage of the most advanced tumor is the best predictor of prognosis, and survival is significantly better in patients with a stage I reference tumor than it is in patients with a higher-staged reference tumor. The survival of patients with synchronous NSCLC with stage I and stage II reference tumors was not different from that of patients with single lung cancer stage II and stage IIIA, respectively. These results indicate that synchronous cancer should be upstaged. ACKNOWLEDGMENT: The authors thank Jane Sykes for her advice in editing the manuscript. References 1 Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 70: Verhagen AF, Van De Wal HJ, Cox AL, et al. Surgical treatment of multiple lung cancers. Thorac Cardiovasc Surg 1989; 37: Ferguson MK, DeMeester TR, DesLauriers J, et al. Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg 1985; 89: Okada M, Tsubota N, Yoshimura M, et al. Operative approach for multiple primary lung carcinomas. J Thorac Cardiovasc Surg 1998; 115: Rosengart TK, Martini N, Ghosn P, et al. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg 1991; 52: Ribet M, Dambron P. Multiple primary lung cancers. Eur J Cardiothorac Surg 1995; 9: Deschamps C, Pairolero PC, Trastek VF, et al. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1990; 99: Yano M, Arai T, Inagaki K, et al. Intrapulmonary satellite nodule of lung cancer as a T factor. Chest 1998; 114: DesLauriers J, Brisson J, Cartier R, et al. Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 1989; 97: Nakajima J, Furuse A, Oka T, et al. Excellent survival in a subgroup of patients with intrapulmonary metastasis of lung cancer. Ann Thorac Surg 1996; 61: Yoshino I, Nakanishi R, Osaki T, et al. Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis. Ann Thorac Surg 1997; 64: CHEST / 118 / 4/ OCTOBER,

7 13 Okada M, Tsubota N, Yoshimura M, et al. Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 1999; 68: Van Rens MThM, Brutel de la Rivière A, Elbers HRJ, et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer stage I, II and IIIA. Chest 2000; 117: Histologic typing of lung tumors. 2nd ed. Geneva, Switzerland: World Health Organization, Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Stat Soc (series A) 1972; 135: Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: Pommier RF, Vetto JT, Lee JT, et al. Synchronous non-small cell lung cancers. Am J Surg 1996; 171: Landreneau RJ, Sugarbaker DJ, Mack MJ, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small cell lung cancer. J Thorac Cardiovasc Surg 1997; 113: Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: Leong PP, Rezai B, Kock WM, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998; 90: Kropveld A, Rozemuller EH, Leppers FGJ, et al. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 1999; 79: Clinical Investigations

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer

Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer Original Article Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer Shuji Haraguchi, MD, 1,2 Kiyoshi Koizumi, MD, 1,2 Tomomi Hirata, MD, 1,2 Kyoji Hirai, MD, 1,2 Iwao Mikami, MD, 1,2 Hirotoshi

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

M expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment

M expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering

More information

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

The distinction of synchronous primary lung cancers

The distinction of synchronous primary lung cancers ORIGINAL ARTICLE Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung Cancers David J. Finley, MD,* Akihiko Yoshizawa, MD, William Travis, MD, Qin Zhou, MA, Venkatraman E. Seshan,

More information

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail

More information

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566

More information

Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,

Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

Staging of lung cancer provides a common language

Staging of lung cancer provides a common language The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International

More information

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

Treatment of oligometastatic NSCLC

Treatment of oligometastatic NSCLC Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic

More information

Multifocal Lung Cancer

Multifocal Lung Cancer Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department

More information

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,

More information

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

PAPER. See Invited Critique at end of article

PAPER. See Invited Critique at end of article PAPER Systematic Postoperative Radiologic Follow-up in Patients With Non Small Cell Lung Cancer for Detecting Second Primary Lung Cancer in Stage IA Jeffrey P. Lamont, MD; James T. Kakuda, MD; David Smith,

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro

More information

T he increasing incidence and poor survival of patients

T he increasing incidence and poor survival of patients 710 LUNG CANCER Survival after resection for primary lung cancer: a population based study of 3211 resected patients T-E Strand, H Rostad, B Møller, J Norstein... See end of article for authors affiliations...

More information

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*

More information

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,

More information

Pulmonary Resection for Metastases from Colorectal Cancer

Pulmonary Resection for Metastases from Colorectal Cancer ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,

More information

The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)

The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative

More information

Characteristics and outcome of patients with second primary lung cancer

Characteristics and outcome of patients with second primary lung cancer ORIGINAL ARTICLE LUNG CANCER Characteristics and outcome of patients with second primary lung cancer Niels Reinmuth 1,2, Andreas Stumpf 1, Patrick Stumpf 1, Thomas Muley 2,3, Sonja Kobinger 2,3, Hans Hoffmann

More information

Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer

Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François

More information

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki

More information

Node-Negative Non-small Cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and

More information

Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J.

Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J. Characteristics of lung cancers detected in the randomized NELSON lung cancer screening trial Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen,

More information

Different trend in multiple primary lung cancer and intrapulmonary metastasis

Different trend in multiple primary lung cancer and intrapulmonary metastasis Shen et al. European Journal of Medical Research (2015) 20:17 DOI 10.1186/s40001-015-0109-5 EUROPEAN JOURNAL OF MEDICAL RESEARCH RESEARCH Open Access Different trend in multiple primary lung cancer and

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a

More information

Surgical resection is the first treatment of choice for

Surgical resection is the first treatment of choice for Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,

More information

THE PROGNOSTIC SIGNIFICANCE OF TUMOR CELL DETECTION IN INTRAOPERATIVE PLEURAL LAVAGE AND LUNG TISSUE CULTURES FOR PATIENTS WITH LUNG CANCER

THE PROGNOSTIC SIGNIFICANCE OF TUMOR CELL DETECTION IN INTRAOPERATIVE PLEURAL LAVAGE AND LUNG TISSUE CULTURES FOR PATIENTS WITH LUNG CANCER THE PROGNOSTIC SIGNIFICANCE OF TUMOR CELL DETECTION IN INTRAOPERATIVE PLEURAL LAVAGE AND LUNG TISSUE CULTURES FOR PATIENTS WITH LUNG CANCER J. Buhr, MD a K. H. Berghfiuser, MD b S. Gonner, MD b C. Kelm,

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor

Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor Dominique Manac h, MD, Marc Riquet, MD, PhD, Jacques Medioni, MD, Françoise Le Pimpec-Barthes, MD, Antoine Dujon,

More information

Chirurgie beim oligo-metastatischen NSCLC

Chirurgie beim oligo-metastatischen NSCLC 24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital

More information

Lung Cancer as a Second Primary Malignancy: Increasing Prevalence and Its Influence on Survival

Lung Cancer as a Second Primary Malignancy: Increasing Prevalence and Its Influence on Survival Ann Surg Oncol (2009) 16:1033 1038 DOI 10.1245/s10434-008-0296-1 ORIGINAL ARTICLE THORACIC ONCOLOGY Lung Cancer as a Second Primary Malignancy: Increasing Prevalence and Its Influence on Survival Silvia

More information

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan

More information

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University Disclosures I have no conflict of interest disclosures

More information

Key words: diameter; lung cancer; lung carcinoma; non-small cell lung cancer; size; staging; T stage; TNM

Key words: diameter; lung cancer; lung carcinoma; non-small cell lung cancer; size; staging; T stage; TNM Diameter of Non-small Cell Lung Cancer Correlates With Long-term Survival* Implications for T Stage Carlos M. Mery, MD, MPH; Anastasia N. Pappas, MSW, MPH; Bryan M. Burt, MD; Raphael Bueno, MD, FCCP; Philip

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

The 7th Edition of TNM in Lung Cancer.

The 7th Edition of TNM in Lung Cancer. 10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic

More information

Lungebevarende resektioner ved lungecancer metode og resultater

Lungebevarende resektioner ved lungecancer metode og resultater Dept. of Cardiothoracic Surgery Lungebevarende resektioner ved lungecancer metode og resultater Henrik Jessen Hansen Dept. of Cardiothoracic Surgery RT 2152, The National University Hospital. Copenhagen,

More information

Microsatellite alteration in plasma DNA discriminates multiple primary lung cancer from metastatic lung cancer

Microsatellite alteration in plasma DNA discriminates multiple primary lung cancer from metastatic lung cancer Original Article Microsatellite alteration in plasma DNA discriminates multiple primary lung cancer from metastatic lung cancer Long Tian 1 *, Xin Wang 1 *, Rujun Zeng 2 *, Cheng Shen 1, Yutian Lai 1,

More information

Subsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy

Subsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy ORIGINAL ARTICLES: GENERAL THORACIC Subsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy Jessica S. Donington, MD, Daniel L. Miller, MD, Charles C. Rowland, BS, Claude Deschamps,

More information

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis < A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay

More information

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

More information

Small-cell lung cancer (SCLC) represents approximately

Small-cell lung cancer (SCLC) represents approximately Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,

More information

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic

More information

sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.

sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ. 1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,

More information

Synchronous Triple Primary Lung Cancers: A Case Report

Synchronous Triple Primary Lung Cancers: A Case Report Case Report Thoracic Imaging http://dx.doi.org/10.3348/kjr.2014.15.5.646 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(5):646-650 Synchronous Triple Primary Lung Cancers: A Case Report Hyun Jung

More information

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi

More information

Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer

Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

Prognostic Value of Histology in Resected Lung Cancer With Emphasis on the Relevance of the Adenocarcinoma Subtyping

Prognostic Value of Histology in Resected Lung Cancer With Emphasis on the Relevance of the Adenocarcinoma Subtyping GENERAL THORIC Prognostic Value of Histology in Resected Lung Cancer With Emphasis on the Relevance of the Adenocarcinoma Subtyping Marc Riquet, MD, PhD, Christophe Foucault, MD, Pascal Berna, MD, Jalal

More information

141 Ann Thorac Surg , Aug Copyright by The Society of Thoracic Surgeons

141 Ann Thorac Surg , Aug Copyright by The Society of Thoracic Surgeons Completion Pneumonectomy: Indications, Complications, and Results Eilis M. McGovern, M.B.B.Ch., Victor F. Trastek, M.D., Peter C. Pairolero, M.D., and W. Spencer Payne, M.D. ABSTRACT From 958 through 985,

More information

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,

More information

Stage IB Nonsmall Cell Lung Cancers: Are They All the Same?

Stage IB Nonsmall Cell Lung Cancers: Are They All the Same? ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,

More information

Induction chemotherapy followed by surgical resection

Induction chemotherapy followed by surgical resection Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser

More information

Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis?

Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Poster No.: C-1887 Congress: ECR 2015 Type: Scientific Exhibit Authors: A. Fujisaki, T. Aoki, S. Kinoshita, Y. Hayashida, Y.

More information

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,

More information

Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer

Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

PULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS

PULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS PULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS Shinji Okumura, MD Haruhiko Kondo, MD Masahiro Tsuboi, MD Haruhiko Nakayama, MD Hisao Asamura, MD Ryosuke Tsuchiya, MD

More information

The prognostic significance of central fibrosis of adenocarcinoma

The prognostic significance of central fibrosis of adenocarcinoma Prognostic Significance of the Size of Central Fibrosis in Peripheral Adenocarcinoma of the Lung Kenji Suzuki, MD, Tomoyuki Yokose, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, Kanji

More information

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy

NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

Lung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection

Lung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

According to the current International Union

According to the current International Union Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell

More information